SWTX - springworkstx.com Trailing Twelve Months Revenue Growth

Brandmark of springworkstx.com (SWTX)

The year-over-year sales growth rate over the trailing four quarters demonstrates revenue dynamics, where 0.00 characterizes this valuation parameter for SpringWorks Therapeutics (SWTX). Environmental policy is limited by FDA regulations on biohazardous waste disposal. The production of targeted drugs has been outsourced to US CMOs to ensure supply stability. Experienced management has successfully transitioned the development of orphan drugs into the commercial phase, confirming their regulatory expertise.

SpringWorks Therapeutics - SWTX Sales Growth YoY (TTM) (period 02/11/2024 - 02/20/2024)

SpringWorks Therapeutics, Inc. - analytical breakdowns and key metrics (SWTX)

- price and consensus price forecast:
Price Rate Chart SpringWorks|SWTX - Analyst Consensus Forecast
- market capitalization statistics:
Market Value SpringWorks|SWTX - Real Price to Acquire Entire Company
- book capitalization data:
Book Price of a Share SpringWorks Therapeutics|SWTX - Book Capitalization|Market-to-Book Ratio springworkstx.com|SWTX - Company Total Assets
- company total debt and liquidity indicators:
Debt to Equity Ratio SpringWorks Therapeutics|SWTX - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital SpringWorks|SWTX - Company Total Debt|Debt to Book Capital SpringWorks Therapeutics, Inc.|SWTX - Company Long-Term Debts|Company Short-Term Loans and Borrowings SpringWorks Therapeutics|Immediate Liquidity springworkstx.com
- financial results and valuation multiples details:
SWTX - Company Net Income|Expected Net Income SpringWorks Therapeutics|SWTX - P/E Multiple|Forward P/E Multiple springworkstx.com|SWTX - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio SpringWorks|SWTX - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months SpringWorks Therapeutics|SWTX - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months springworkstx.com|SWTX - Earnings per share growth in current year|Net earnings per share change forecast for next year SpringWorks Therapeutics
- sales revenue and business income indicators:
SWTX - Company Revenue|Company Future Revenue SpringWorks|SWTX - P/S Multiple|Market Cap to Expected Sales Ratio SpringWorks Therapeutics Inc.|SWTX - Sales Growth YoY (Last Twelve Months)
Fundamental company valuation:SpringWorks SWTX
Flagship merchandise of springworkstx.com

The development of targeted therapies for rare tumors by elite oncologists at SpringWorks Therapeutics (SWTX) requires a steady influx of capital to sustain the innovation cycle. Year-over-year (TTM) sales growth measures the relative change in revenue over a 12-month rolling period, allowing investors to assess real demand for drugs by smoothing out seasonality and to detect any stagnation in the year-over-year (TTM) sales growth trend in a timely manner.

Who SpringWorks Therapeutics competes with

Revenue Growth Rate YoY (Last Twelve Months) Genmab US|Exelixis Inc - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Nuvalent|KYMR (Kymera Therapeutics) - Revenue Growth YoY (Last 12 Months)|IDYA: Revenue Change YoY (Last 12 Months)|ELVN (enliventherapeutics.com) - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth ORIC Pharma ORIC|Sales Growth YoY (TTM) RLAY|Nurix Therapeutics, Inc. - Sales Growth YoY (Last 12 Months)|Tyra Biosciences - Revenue Growth YoY (Last 12 Months)|Revenue Dynamics YoY (Last Twelve Months) VSTM|GLUE: Revenue Growth YoY (Last 12 Months)|Cullinan Therapeutics Inc - Revenue Change YoY (Last 12 Months)|IMRX: Sales Growth YoY (TTM)|C4 Therapeutics, Inc. - Revenue Dynamics YoY (Last Twelve Months)|BDTX (Black Diamond Therapeutics, Inc) - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Repare Therapeutics, Inc. RPTX|Sales Growth YoY (Last Twelve Months) PMV Pharma (PMVP)|KPTI (Karyopharm Therapeutics Inc.) - Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (TTM) PPCB (Propanc Biopharma Inc.)|Sales Growth YoY (TTM) cyclacel.com BGMS|AADI - Sales Growth YoY (Last Twelve Months)|Trailing Twelve Months Sales Growth ALRN|BPMC (blueprintmedicines.com) - Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth GlycoMimetics Inc. (GLYC)